Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas.

Jørgensen JM, Sørensen FB, Bendix K, Nielsen JL, Funder A, Karkkainen MJ, Tainola T, Sørensen AB, Pedersen FS, D'Amore F.

Leuk Lymphoma. 2009 Oct;50(10):1647-60. doi: 10.1080/10428190903156729.

PMID:
19701853
2.

Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos.

Haiko P, Makinen T, Keskitalo S, Taipale J, Karkkainen MJ, Baldwin ME, Stacker SA, Achen MG, Alitalo K.

Mol Cell Biol. 2008 Aug;28(15):4843-50. doi: 10.1128/MCB.02214-07. Epub 2008 Jun 2.

3.

Transcapillary fluid balance consequences of missing initial lymphatics studied in a mouse model of primary lymphoedema.

Karlsen TV, Karkkainen MJ, Alitalo K, Wiig H.

J Physiol. 2006 Jul 15;574(Pt 2):583-96. Epub 2006 May 4.

4.

VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain.

Le Bras B, Barallobre MJ, Homman-Ludiye J, Ny A, Wyns S, Tammela T, Haiko P, Karkkainen MJ, Yuan L, Muriel MP, Chatzopoulou E, Bréant C, Zalc B, Carmeliet P, Alitalo K, Eichmann A, Thomas JL.

Nat Neurosci. 2006 Mar;9(3):340-8. Epub 2006 Feb 5.

PMID:
16462734
5.

Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation.

Saharinen P, Tammela T, Karkkainen MJ, Alitalo K.

Trends Immunol. 2004 Jul;25(7):387-95. Review. No abstract available.

PMID:
15207507
6.

Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis.

He Y, Rajantie I, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P, Alitalo K.

Cancer Res. 2004 Jun 1;64(11):3737-40.

7.

Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.

Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K.

Nat Immunol. 2004 Jan;5(1):74-80. Epub 2003 Nov 23.

PMID:
14634646
8.

Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites.

Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K, Claesson-Welsh L.

J Biol Chem. 2003 Oct 17;278(42):40973-9. Epub 2003 Jul 24.

9.

Insights into the molecular pathogenesis and targeted treatment of lymphedema.

Saaristo A, Karkkainen MJ, Alitalo K.

Ann N Y Acad Sci. 2002 Dec;979:94-110. Review.

PMID:
12543720
10.

Therapeutic lymphangiogenesis with human recombinant VEGF-C.

Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB, Dakhil N, Spilman S, Goris ML, Strauss HW, Quertermous T, Alitalo K, Rockson SG.

FASEB J. 2002 Dec;16(14):1985-7. Epub 2002 Oct 18.

PMID:
12397087
11.

Abnormal lymphatic vessel development in neuropilin 2 mutant mice.

Yuan L, Moyon D, Pardanaud L, Bréant C, Karkkainen MJ, Alitalo K, Eichmann A.

Development. 2002 Oct;129(20):4797-806.

12.

Lymphangiogenic gene therapy with minimal blood vascular side effects.

Saaristo A, Veikkola T, Tammela T, Enholm B, Karkkainen MJ, Pajusola K, Bueler H, Ylä-Herttuala S, Alitalo K.

J Exp Med. 2002 Sep 16;196(6):719-30.

13.

Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.

Saaristo A, Veikkola T, Enholm B, Hytönen M, Arola J, Pajusola K, Turunen P, Jeltsch M, Karkkainen MJ, Kerjaschki D, Bueler H, Ylä-Herttuala S, Alitalo K.

FASEB J. 2002 Jul;16(9):1041-9.

PMID:
12087065
14.

Lymphatic endothelial regulation, lymphoedema, and lymph node metastasis.

Karkkainen MJ, Alitalo K.

Semin Cell Dev Biol. 2002 Feb;13(1):9-18. Review.

PMID:
11969367
15.

Lymphatic endothelium: a new frontier of metastasis research.

Karkkainen MJ, Mäkinen T, Alitalo K.

Nat Cell Biol. 2002 Jan;4(1):E2-5. Review.

PMID:
11780131
16.

A model for gene therapy of human hereditary lymphedema.

Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, Bueler H, Eichmann A, Kauppinen R, Kettunen MI, Yla-Herttuala S, Finegold DN, Ferrell RE, Alitalo K.

Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12677-82. Epub 2001 Oct 9.

17.

Molecular regulation of lymphangiogenesis and targets for tissue oedema.

Karkkainen MJ, Jussila L, Ferrell RE, Finegold DN, Alitalo K.

Trends Mol Med. 2001 Jan;7(1):18-22. Review.

PMID:
11427983
18.

VEGFR3 gene structure, regulatory region, and sequence polymorphisms.

Iljin K, Karkkainen MJ, Lawrence EC, Kimak MA, Uutela M, Taipale J, Pajusola K, Alhonen L, Halmekytö M, Finegold DN, Ferrell RE, Alitalo K.

FASEB J. 2001 Apr;15(6):1028-36.

PMID:
11292664
19.

Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.

Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Ylä-Herttuala S, Jäättelä M, Alitalo K.

Cancer Res. 2001 Mar 1;61(5):1786-90.

20.

The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man.

Baldwin ME, Catimel B, Nice EC, Roufail S, Hall NE, Stenvers KL, Karkkainen MJ, Alitalo K, Stacker SA, Achen MG.

J Biol Chem. 2001 Jun 1;276(22):19166-71. Epub 2001 Feb 20.

21.

Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis.

Karkkainen MJ, Petrova TV.

Oncogene. 2000 Nov 20;19(49):5598-605. Review.

22.

Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase.

Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M.

Am J Hum Genet. 2000 Aug;67(2):295-301. Epub 2000 Jun 9.

23.

Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema.

Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN.

Nat Genet. 2000 Jun;25(2):153-9.

PMID:
10835628
24.

Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells.

Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K, Härkönen PL.

Mol Cell Endocrinol. 1999 Mar 25;149(1-2):29-40.

PMID:
10375015
25.

Overexpression of VEGF in testis and epididymis causes infertility in transgenic mice: evidence for nonendothelial targets for VEGF.

Korpelainen EI, Karkkainen MJ, Tenhunen A, Lakso M, Rauvala H, Vierula M, Parvinen M, Alitalo K.

J Cell Biol. 1998 Dec 14;143(6):1705-12.

Supplemental Content

Loading ...
Support Center